Individual variation in side effects depends more on your genetics, starting dose, and metabolism than on whether you choose injection or oral
In 2022, semaglutide, dulaglutide, and tirzepatide were all listed as currently in shortage per the FDA
They are a bit pricy, but are more portable than other solutions
In the DURATION-8 trial, dapagliflozin as monotherapy and in combination with EX-QW showed trends favoring improvements in LFC, glucose and lipid metabolism, and liver fibrosis scores at the end of the study, but no significant statistical differences were observed
In experimental models, body weight gains have been observed, possibly connected to both food intake regulation and hormonal influences independent of growth hormone
Lower blood sugar levels